Literature DB >> 25787973

Mitral valve repair for rheumatic mitral regurgitation: Mid-term results.

Somchai Waikittipong1.   

Abstract

AIM: This retrospective study was undertaken to evaluate the midterm results of mitral valve repair for rheumatic mitral regurgitation, in term of survival rate and late valve failure.
METHODS: From January 2003 to January 2014, 97 patients underwent mitral valve repair in our hospital. Age ranged from 8 to 74 years, mean 24 ± 1.4 years; 74 (76%) patients were female. Mean preoperative functional class was 2.47 ± 0.07. Mean preoperative ejection fraction was 59.9% ± 2%. The lesions were pure mitral regurgitation in 79 (81.4%) patients, predominant mitral regurgitation with stenosis in 9 (9.3%), and predominant mitral stenosis with regurgitation in 9 (9.3%). Seventy-one (73%) patients were in normal sinus rhythm.
RESULTS: One patient died in the postoperative period, and 8 were lost during follow-up. Follow-up time ranged from 6 to 137 months, mean 58.8 ± 4.2 months. There were 6 late deaths. Actuarial survival at 5 and 10 years was 95.5% and 89.2%, respectively. Twenty-seven (27.8%) patients had mitral regurgitation during follow-up, and 7 underwent reoperation with no hospital mortality. Freedom from reoperation at 5 and 10 years was 94.5% and 82.7%, respectively. Freedom from reoperation or progression of mitral regurgitation at 5 and 10 years was 70.4% and 61.8%, respectively. Freedom from all late events at 5 and 10 years was 68 % and 56.4%, respectively.
CONCLUSIONS: Mitral valve repair for rheumatic mitral regurgitation is associated with a significant rate of valve failure and reoperation. However, it has a satisfactory survival rate and is a good alternative to valve replacement, especially for young patients, to avoid the life-long risks of a prosthetic valve.
© The Author(s) 2015.

Entities:  

Keywords:  Mitral valve; mitral valve insufficiency; postoperative complications; rheumatic heart disease; treatment outcome

Mesh:

Year:  2015        PMID: 25787973     DOI: 10.1177/0218492315576282

Source DB:  PubMed          Journal:  Asian Cardiovasc Thorac Ann        ISSN: 0218-4923


  6 in total

1.  A meta-analysis of late outcomes of mitral valve repair in patients with rheumatic heart disease.

Authors:  Jin-Tao Fu; Mohammad Sharif Popal; Hai-Bo Zhang; Wei Han; Qiu-Ming Hu; Xu Meng; Chun-Ye Ma
Journal:  J Thorac Dis       Date:  2017-11       Impact factor: 2.895

Review 2.  Group A Streptococcus, Acute Rheumatic Fever and Rheumatic Heart Disease: Epidemiology and Clinical Considerations.

Authors:  Liesl J Zühlke; Andrea Beaton; Mark E Engel; Christopher T Hugo-Hamman; Ganesan Karthikeyan; Judith M Katzenellenbogen; Ntobeko Ntusi; Anna P Ralph; Anita Saxena; Pierre R Smeesters; David Watkins; Peter Zilla; Jonathan Carapetis
Journal:  Curr Treat Options Cardiovasc Med       Date:  2017-02

3.  Anti-Thymocyte Globulin Prophylaxis in Patients With Hematological Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: An Updated Meta-Analysis.

Authors:  Xue Yang; Dongjun Li; Yao Xie
Journal:  Front Oncol       Date:  2021-08-20       Impact factor: 6.244

4.  A Comparative Study on Surgical Treatment of Valvular Heart Disease between High-Volume Cardiac Centers in China and STS Data.

Authors:  Hongyuan Lin; Jiamiao Gong; Yongjian Wu; Zhe Zheng; Jianfeng Hou
Journal:  J Cardiovasc Dev Dis       Date:  2022-07-02

5.  A predictor for mitral valve repair in patient with rheumatic heart disease: the bending angle of anterior mitral leaflet.

Authors:  Jin-Tao Fu; Mohammad Sharif Popal; Yu-Qing Jiao; Hai-Bo Zhang; Shuai Zheng; Qiu-Ming Hu; Wei Han; Xu Meng
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

Review 6.  Current Perspectives on Contemporary Rheumatic Mitral Valve Repair.

Authors:  Chaninda Dejsupa; Taweesak Chotivatanapong; Massimo Caputo; Hunaid A Vohra
Journal:  Innovations (Phila)       Date:  2021-09-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.